Skip to content

Efficacy of Allergen-specific Immunotherapy for Allergic Rhinitis and its Influencing Factors and Biomarkers

Efficacy of Allergen-specific Immunotherapy for Allergic Rhinitis and its Influencing Factors and Biomarkers

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115458
Enrollment
Unknown
Registered
2025-12-26
Start date
2025-09-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

SCIT group:None
SLIT group:None

Sponsors

The First Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Skin prick test (>=++) or serum specific immunoglobulin E (sIgE) to diagnose dust mite positivity; 2. Age range of 5 to 60 years old; 3. Complete clinical data; 4. Continuously receive AIT for at least 6 months; 5. Patients and their families provide informed consent and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Not cooperating with follow-up visits; 2. Multiple interruptions in treatment; 3. Existence of tumors or mental abnormalities; 4. Severe uncontrollable asthma or irreversible respiratory obstructive diseases; 5. Has cardiovascular and cerebrovascular diseases and is currently taking beta blockers; 6. Immunodeficiency or autoimmune diseases.

Design outcomes

Primary

MeasureTime frame
visual analogue scale score;

Secondary

MeasureTime frame
Total nasal symptom score;Total ocular symptom score;Total asthma symptom score;Total symptom score;Rhinoconjunctivitis Quality of Life Questionnaire;

Countries

China

Contacts

Public ContactXu Rui

The First Affiliated Hospital of Sun Yat-sen University

gzxur2708@163.com+86 138 0250 9090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026